STOCK TITAN

Pacira BioSciences closes $36.50-a-share Viatris merger

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC 14D9/A

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) completed its merger with Viatris on November 17, 2026, after Viatris subsidiary Purchaser completed a cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. The offer expired November 16 and was not extended. Holders validly tendered 32,929,780 shares; those shares, together with shares already owned by Purchaser and its affiliates, represented approximately 66.46% of Pacira’s issued and outstanding shares at expiration, satisfying the Minimum Condition.

Purchaser accepted the validly tendered shares for payment on November 17, and the merger closed that day under Section 251(h) without a Pacira stockholder vote. Each outstanding share immediately before the merger, except shares held by Pacira, Viatris-related entities, and stockholders exercising appraisal rights, converted into the right to receive the offer price. Pacira survived as a wholly owned Viatris subsidiary; its shares will be delisted from the Nasdaq Global Select Market and deregistered under the Exchange Act.

Tendered shares 32,929,780 shares Validly tendered and not properly withdrawn before the offer expired.
Tendered shares and shares already owned Approximately 66.46% Combined amount as a percentage of Pacira’s issued and outstanding shares at the offer’s expiration.
Offer price $36.50 per share Cash, net of applicable withholding taxes and without interest.
Minimum Condition technical
"satisfied the Minimum Condition"
statutory rights of appraisal regulatory
"properly exercised and perfected their statutory rights of appraisal under the DGCL"
Section 251(h) regulatory
"in accordance with Section 251(h) of the DGCL"
Section 251(h) is a provision in Delaware corporate law that lets a company complete a merger without holding a separate shareholder vote if a prior, qualifying tender offer already secured the required number of shares on the same terms. For investors, it matters because it shortens the timetable and reduces the risk that a merger will be blocked by a follow-up vote—think of it as a shortcut that finalizes a deal once enough stockholders have already agreed.
Effective Time technical
"At the Effective Time and as a result of the Merger"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash price did the tender offer provide for PCRX shares?

Purchaser’s offer was $36.50 in cash per Pacira share, net of applicable withholding taxes and without interest. The offer expired November 16, 2026, and the merger closed November 17, 2026.

How many PCRX shares were tendered in the Viatris offer?

Holders validly tendered 32,929,780 shares. Together with shares then owned by Purchaser and its affiliates, they represented approximately 66.46% of Pacira’s issued and outstanding shares at the offer’s expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



SCHEDULE 14D-9

Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. 3)



Pacira BioSciences, Inc.
(Name of Subject Company)



Pacira BioSciences, Inc.
(Name of Person Filing Statement)



Common Stock, $0.001 par value per share
(Title of Class of Securities)



695127100
(CUSIP Number of Class of Securities)



Frank D. Lee
Chief Executive Officer
Pacira BioSciences, Inc.
2000 Sierra Point Parkway, Suite 900
Brisbane, California 94005
(650) 242-8052
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person Filing Statement)



With copies to:
Jason Day
Jonathan S. Schulman
Ashurst Perkins Coie US LLP
1900 Sixteenth Street, Suite 1400
Denver, Colorado 80202
(303) 291-2300


☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.




This Amendment No. 3 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as further amended or supplemented from time to time, the “Schedule 14D-9”) previously filed by Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), with the U.S. Securities and Exchange Commission (the “SEC”) on October 30, 2026, relating to the Tender Offer Statement on Schedule TO filed with the SEC on October 30, 2026 (together with any amendments and supplements thereto, the “Schedule TO”) by Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Viatris (“Purchaser”), pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026 (as amended, modified or supplemented from time to time, the “Merger Agreement”), among Viatris, Purchaser and Pacira. The Schedule TO relates to the tender offer by Purchaser to acquire all of the outstanding shares of common stock of Pacira, $0.001 par value per share (collectively, the “Shares”), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Merger Agreement.

Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment. This Amendment is being filed to reflect certain updates as set forth below.

Item 8. Additional Information.

Item 8 “Additional Information” of the Schedule 14D-9 is hereby amended and supplemented by inserting the following text immediately before the section entitled “Cautionary Note Regarding Forward-Looking Statements”:

“Expiration of the Offering Period; Completion of the Merger

The Offer and related withdrawal rights expired as scheduled at one minute following 11:59 p.m., Eastern Time, on November 16, 2026, and the Offer was not extended. Purchaser was advised by Equiniti Trust Company, LLC, the depositary and paying agent for the Offer, that a total of 32,929,780 Shares, together with the Shares then owned by Purchaser and its “affiliates” (as such term is defined in Section 251(h)(6)(a) of the DGCL), were validly tendered (and not properly withdrawn) pursuant to the Offer prior to the Expiration Date (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h)(6)(f) of the DGCL, by the “depository,” as such term is defined in Section 251(h)(6)(c) of the DGCL), representing approximately 66.46% of the issued and outstanding Shares as of the Expiration Date.

Accordingly, the number of Shares validly tendered (and not properly withdrawn) and received by the depository pursuant to the Offer, together with the Shares then owned by Purchaser and its affiliates, satisfied the Minimum Condition, and all other conditions to the consummation of the Offer had been satisfied or waived. As a result of the satisfaction of the Minimum Condition and each of the other conditions to the Offer, on November 17, 2026, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not properly withdrawn) pursuant to the Offer.

Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and the parties to the Merger Agreement consummated the Merger on November 17, 2026. Pursuant to the Merger Agreement, at the Effective Time, Purchaser was merged with and into Pacira, without a vote on the adoption of the Merger Agreement by Pacira’s stockholders, in accordance with Section 251(h) of the DGCL, with Pacira continuing as the surviving corporation of the Merger and as a wholly owned subsidiary of Viatris. At the Effective Time and as a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time (other than Shares held (i) by Pacira or its subsidiaries (including Shares held in Pacira’s treasury), (ii) by Viatris, Purchaser, or any other direct or indirect wholly owned subsidiary of Viatris, or (iii) by stockholders of Pacira who have properly exercised and perfected their statutory rights of appraisal under the DGCL) was automatically converted into the right to receive the Offer Price.

Following the consummation of the Merger, the Shares will be delisted from the Nasdaq Global Select Market and will be deregistered under the Exchange Act.”

Item 9. Exhibits.

Item 9 “Exhibits” of the Schedule 14D-9 is hereby amended and supplemented by inserting the following as Exhibit (a)(5)(L)*:

“Press Release issued by Viatris Inc. on November 17, 2026 (incorporated herein by reference to Exhibit (a)(5)(E) to Amendment No. 2 to the Schedule TO filed on November 17, 2026 by Viatris and Purchaser).”


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

   
PACIRA BIOSCIENCES, INC.
     
 
By:
/s/ Michael Rainerman
 
Name:
Michael Rainerman
 
Title:
President
Dated: November 17, 2026
   


Keep reading